May 2, 2024
Outer Limits
AGI — Money is No Object
Sam Altman just hinted at a paradigm shift in GPT architecture.
6 min read
by Jeff Brown
Profiting from the leading edge of tech, with high-tech insider and angel investor Jeff Brown.
Sign Up
The only place in the universe to find insights and analysis on the world of tech, the markets, and the perpetual chaos around us, from high-tech executive and angel investor Jeff Brown. Please enter your email to start getting his personal intel on what’s happening behind closed doors.
Sam Altman just hinted at a paradigm shift in GPT architecture.
While government squanders, private nuclear fusion companies have gotten busy.
Somehow the tides have turned in Silicon Valley. And building defense technology is no longer taboo.
By the end of this year, the world will figure out what Musk and his team at Tesla have done.
What effect will the November elections have on biotech investments?
Are these three new AI entrants worthy of our buy list?
Biotech has pulled back, so is now the time to strike?
When it comes to biotech stock prices, this one factor has the power to create a major tailwind — or headwind — for the entire sector, regardless of what’s happening with each individual company.
Few have heard the story of Early Stage Trader...
Jeff Brown has more than three decades of experience as a high-tech executive, investor, and investment research analyst.
He's widely known for his candid and untarnished analysis and insights into the world of tech, biotech, economics, and investment research. Millions have read and enjoyed his work at his most recent role as founder and chief investment analyst at Brownstone Research, where he worked and published for 8 years.